A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(22 sites)

United States

Cincinnati Childrens Hospital, Cincinnati, Ohio

Legacy Emanuel Research Hosp Portland, Portland, Oregon

Canada

Novartis Investigative Site, Montreal, Quebec

France

Novartis Investigative Site, Bordeaux